Valneva : Positive opinion from the CHMP for VLA2001
>An alternative eagerly awaited by Europeans... - Valneva announced yesterday during trading that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended market approval for VLA2001 (Covid-19 vaccine) for use as a primary vaccination in adults between 18-55 years. The CHMP therefore concluded that the clinical results were “solid and met the European Union's efficacy, safety and quality criteria”. To recap, the level of neutralising antibodies ...Valneva, together with its subsidiaries, is focused on vaccine development and antibody discovery. Co. generates revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®/JESPECT®), commercial partnerships around a portfolio of product candidates and licensed technology platforms (EB66® cell line, VIVA,Screen antibody discovery technology, and the IC31® adjuvant) developed by Co. Related business activities include product research and development, regulatory and clinical activities, manufacturing of commercial product and advanced clinical product candidates, as well as administrative, corporate development, and marketing and sales activities.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.